---
title: "Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291802702.md"
description: "On July 6, 2026, Belite Bio, Inc (NASDAQ: BLTE), a company specializing in developing drugs for degenerative retinal diseases, revealed its upcoming participation in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. Belite Bio focuses on creating innovative therapeutics for these conditions due to their substantial unmet medical needs."
datetime: "2026-07-06T12:01:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291802702.md)
  - [en](https://longbridge.com/en/news/291802702.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291802702.md)
generator: "portal-rs"
---

# Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

On July 6, 2026, Belite Bio, Inc (NASDAQ: BLTE), a company specializing in developing drugs for degenerative retinal diseases, revealed its upcoming participation in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. Belite Bio focuses on creating innovative therapeutics for these conditions due to their substantial unmet medical needs.

### Related Stocks

- [BLTE.US](https://longbridge.com/en/quote/BLTE.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Belite Bio joins H.C. Wainwright ophthalmology virtual conference panel July 22](https://longbridge.com/en/news/292763511.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [FibroBiologics wins new US patent for degenerative disc disease treatment using fibroblast conditioned media](https://longbridge.com/en/news/297652903.md)
- [Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports](https://longbridge.com/en/news/297596287.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**